ARTICLE | Company News
Intercell, Novartis deal
August 10, 2015 7:00 AM UTC
Valneva SE (Euronext:VLA; VSE:VLA, Lyon, France) is terminating its marketing and distribution agreement with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) for Japanese Encephalitis vaccine Ixiaro. Valneva will regain rights to sell the product worldwide, excluding Australia, New Zealand and parts of Asia. The transition is expected to be completed early next year. Valneva said it does not owe a termination fee. ...